Epigenetic therapy for myelodysplastic syndromes has entered center stage.
Lübbert
Michael
M
University of Freiburg Medical Center, Freiburg, Germany. michael.luebbert@uniklinik-freiburg.de
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019175:DNA Methylation; D044127:Epigenesis, Genetic; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics
D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors